MANY MINDEDMerck's New Cholesterol Pill Wins FDA Approval at a Lower Price
The FDA on Thursday approved enlicitide, sold by Merck under the brand name Lipfendra, a daily pill that lowers LDL cholesterol far below what statins typically achieve. In clinical trials it brought LDL levels down to 50, 60, or lower, against the above-100 readings common in adults not on cholesterol drugs. The drug works by inhibiting the PCSK9 protein, the same target as existing injectable therapies.
The difference is form and price. PCSK9 inhibitors already exist, but only as injections listing at $500 to $600 a month or more, and just 1 percent of roughly six million eligible patients use them. Lipfendra will list at $315 for a 30-day supply and comes as a pill rather than a shot. Merck says it will be available within a few weeks.
The abundance case is about reach. Heart disease is among the most common killers, and PCSK9 inhibitors can cut heart attack risk by 20 percent in high-risk patients. A cheaper, needle-free option lowers two of the biggest barriers keeping eligible people off a proven therapy, potentially moving a large population toward the LDL targets clinical guidelines recommend.
What to watch is uptake and real-world pricing after insurance, since a lower list price does not guarantee affordability at the pharmacy counter. The efficacy figures come from clinical trials, and the reporting here traces to a New York Times piece. Cardiologists who welcomed the approval were not tied to Merck, but long-term outcome data will tell whether the pill delivers the heart-attack reductions its class promises.
Source: HumanProgress